of metastasis, CCL2 guides tumor cell migration by interacting with CCR2 expressed on the surface of cancer cells. 9, 10 CCL2 also induces expression of MMP2 and MMP9 in cancer cells, both of which facilitate cancer cell invasion, 11, 12 and it promotes the intra-and extravasation of cancer cells by attracting TAM. 13 TAM and MDSC recruited by CCL2 trigger an angiogenic switch 14, 15 and suppress immune-mediated attack of cancer cells. 16 In addition, CCL2 attracts cancer cells to future sites of metastasis and supports their proliferation and survival at such premetastatic niches. 17 Increased levels of CCL2 in tumor cells or serum have been detected in individuals with melanoma or with breast, prostate, colorectal, gastric, or ovarian cancer, and they are frequently associated with disease progression, tumor grade, or metastasis, suggestive of the clinical importance of the CCL2-CCR2 signaling pathway. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] These observations also suggest that targeting of the CCL2-CCR2 axis might be an effective strategy for cancer treatment.
Herein, we review currently available agents that target the CCL2-CCR2 axis and studies of their efficacy for cancer treatment.
Among such agents, we focus on an organogermanium compound, PGe (3-oxygermylpropionic acid polymer), that has been shown to act as a blocker of CCR2 signaling. [34] [35] [36] showed that it induced a transient decrease in the concentration of CCL2 in serum, but that this decrease was followed by an increase to levels higher than pre- 
| INHIB ITOR S OF THE CCL 2-CCR A XIS

| Antibodies to CCL2 and CCR2
| Small-molecule compounds
As an alternative to neutralizing antibodies, chemical agents (Table 1) . A double-blind controlled trial of PGe was conducted with HBV antigen-positive chronic hepatitis in the late 1980s. 46 Titers of antibodies to HBV were significantly increased after treatment in the PGe group, whereas HBV antigen titers were significantly lower in the PGe group than in the placebo group. Serum HBV antigen levels and serum (ALT levels were significantly lower in the PGe group than in the control group at 12 and 16 weeks after treatment onset. PGe is also effective for the treatment of other types of liver injury in mice.
| CHEMIC AL AND PHARMACOLOG IC AL PROPERTIE S OF PROPAG ERMANIUM
Giving oral PGe thus inhibited the development of liver injury induced by injection of concanavalin A or lipopolysaccharide injection,
Corynebacterium parvum infection or genetic deletion of fumarylacetoacetate hydrolase. [47] [48] [49] PGe also has therapeutic effects in other inflammatory diseases such as atherosclerosis, 50,51 fibrosis, [52] [53] [54] and obesity induced by a high-fat diet.
55-57
| PROPAG ERMANI UM FOR TRE ATMENT OF C AN CER
Recent studies have shown that interference with key mediators of metastatic development is a promising alternative strategy for cancer treatment. The CCL2-CCR2 signaling pathway is an attractive therapeutic target in such an approach, given its key functions in metastasis described above. We previously showed that Fbxw7 (also known as patients, and progressive disease in two patients. 60 After discontinuation of PGe, the multiple myeloma progressed in two patients F I G U R E 2 Solid and water-soluble forms of propagermanium (PGe) and repagermanium (RGe). GeSP, germanium straight-chain polymer who had achieved stable disease and in the two patients who had achieved partial remission. Phase 1 studies are also ongoing to evaluate the safety and effectiveness of PGe for patients with breast cancer (UMIN000022494), pancreatic cancer (UMIN000017715), and colorectal cancer (UMIN000022129).
| CON CLUS IONS
The CCL2-CCR2 signaling pathway plays a central role in inflammatory diseases including cancer metastasis. Treatment targeted to CCR2 such as that with PGe alleviates pathological phenotypes associated with these diseases. PGe has been approved for the treatment of hepatitis B in Japan, and its bioavailability and safety have been established. Drug repositioning, which aims to identify new indications for existing drugs, has been gaining popularity as an approach to drug discovery. PGe is thus a candidate for drug repositioning with regard to its suppressive effect on cancer metastasis. Further studies will determine whether this agent is truly effective for the treatment of cancer.
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F I G U R E 3
Model for the promotion of cancer metastasis by loss of Fbxw7 in the host environment and its suppression by treatment with propagermanium (PGe). Excessive signaling by Notch1 due to the impairment of its degradation as a result of Fbxw7 ablation gives rise to increased production of chemokine C-C motif chemokine 2 (CCL2). Consequent recruitment of monocytic myeloid-derived suppressor cells (Mo-MDSC) and tumor-associated macrophages (TAM) facilitates metastatic tumor growth. PGe suppresses CCL2-dependent recruitment of Mo-MDSC and TAM and thereby attenuates cancer metastasis. CCR2, C-C chemokine receptor type 2
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